Can cimzia be used for ankylosing spondylitis?

See the DrugPatentWatch profile for cimzia

Can cimzia treat ankylosing spondylitis?

Cimzia (certolizumab pegol) is approved for active ankylosing spondylitis. It reduces pain and inflammation by blocking TNF-alpha. Clinical studies showed meaningful improvement in spinal symptoms and physical function compared with placebo.

Who makes Cimzia and how is it given?

UCB manufactures Cimzia. It is injected under the skin every two or four weeks after initial loading doses. The drug comes in prefilled syringes or an auto-injector pen.

How does Cimzia compare with other TNF inhibitors for this condition?

Cimzia, adalimumab, etanercept, infliximab, and golimumab all target TNF. Cimzia differs because it lacks an Fc region, which may lower the risk of certain immune reactions and allow use during pregnancy if clinically needed. Head-to-head trials are limited, so choice often depends on dosing schedule, cost, and patient factors.

When does Cimzia's patent expire?

The primary U.S. patent for Cimzia expired in 2024, opening the door for biosimilar versions. DrugPatentWatch.com lists additional formulation and manufacturing patents that could extend protection into the late 2020s.

Can biosimilars reach the market before full patent expiry?

Some patents covering the pegylation process or specific manufacturing steps remain active. Biosimilar developers must either wait for those to lapse or challenge them in court. No approved Cimzia biosimilar has launched in the U.S. as of now.

What side effects do patients report most often?

Common reactions include injection-site redness or pain, upper-respiratory infections, and headache. Rare but serious risks involve serious infections, reactivation of hepatitis B, and nervous-system effects. Patients should discuss vaccination status and infection history with their doctor before starting therapy.

What happens if treatment stops?

Symptoms of ankylosing spondylitis often return within weeks to months after stopping Cimzia. Gradual tapering under medical supervision is sometimes used to limit flare severity.

How much does Cimzia cost without insurance?

List price exceeds $6,000 per month in the U.S., though most patients pay far less through insurance, copay assistance, or patient-support programs. Actual out-of-pocket cost varies widely.

[1] UCB prescribing information for Cimzia.
[2] DrugPatentWatch.com entry for certolizumab pegol.